Skip to content

Revvity RVTY Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Danaher logo
DanaherDHR
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
Agilent Technologies logo
Agilent TechnologiesA
IQVIA logo
IQVIAIQV
Idexx Laboratories logo
Idexx LaboratoriesIDXX

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's common stock, shares authorized (in shares)?
Revvity (RVTY) reported common stock, shares authorized (in shares) of $300M in Q1 2026.
How has Revvity's common stock, shares authorized (in shares) changed year-over-year?
Revvity's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $300M to $300M.
What is the long-term trend for Revvity's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Revvity's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $300M to $300M.